Akero shares double after preliminary results from mid-stage trial for liver disease drug

Akero Therapeutics

27/01/2025 11:48

Jan 27 (Reuters) - Akero Therapeutics  AKRO.O  shares
gained 106% before the bell on Monday after the company reported
results from a mid-stage trial studying its lead drug in
patients with a type of liver disease.
    The experimental drug efruxifermin is being studied in
patients with scarring due to a type of fatty liver disease
known as metabolic dysfunction-associated steatohepatitis.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Sriparna.Roy@thomsonreuters.com;))